GlassScriptPhysician profile
Timothy W Jones
NPI 1265517189
$2,026.01
in general payments reported to CMS, 2019-2025
31 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $60.85 · 2022: $19.66 · 2023: $372 · 2024: $639 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.56 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $708.39 | 2023-2025 | Inspire |
| Stryker Corporation | $197.97 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sunovion Pharmaceuticals INC. | $130.98 | 2019 | |
| Allergan, INC. | $108.04 | 2019-2020 | |
| Itamar Medical INC | $107.62 | 2023-2024 | Watchpatone |
| Janssen Biotech, INC. | $101.94 | 2023 | Rybrevant |
| Glaxosmithkline, LLC. | $61.00 | 2019-2025 | Nucala |
| Ani Pharmaceuticals, INC. | $50.59 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.72 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $35.39 | 2025 | Lumryz |
| Mylan Specialty L.P. | $35.34 | 2019-2022 | |
| Phadia US INC. | $32.84 | 2023-2025 | Immunocap |
| Insmed, INC. | $32.48 | 2023-2024 | Arikayce |
| Jazz Pharmaceuticals INC. | $31.83 | 2024 | |
| Genzyme Corporation | $29.61 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.44 | 2023 | Tezspire |
| Zoll Respicardia, INC. | $24.49 | 2025 | Remede System |
| Astrazeneca Pharmaceuticals LP | $24.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.83 | 2024 | Glassia |
| Actelion Pharmaceuticals US, INC. | $23.62 | 2023 | Uptravi, Opsumit |
| Pulmonx Corporation | $22.50 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Baxter Healthcare | $21.95 | 2023 | Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $21.93 | 2025 | Zepbound |
| Boston Scientific Corporation | $21.50 | 2023 | Exalt Model D |
| Advanced Respiratory, INC | $19.94 | 2019 | |
| Axsome Therapeutics, INC. | $17.79 | 2023 | Sunosi |
| Circassia INC. | $17.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.61 | 2019 | |
| Medtronic USA, INC. | $14.83 | 2019 | |
| Fisher & Paykel Healthcare INC | $13.03 | 2019 | |
| Merck Sharp & Dohme LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.